Bendamustine [BEN1]

The first line treatment of low grade lymphoma where all the following criteria are met:

  1. Application made by and first cycle of systemic anti-cancer therapy to be prescribed by a consultant specialist specifically trained and accredited in the use of systemic anti-cancer therapy
  2. Low grade non-Hodgkin’s lymphoma
  3. Option for 1st-line chemotherapy only
  4. To be used within the treating Trust’s governance framework, as Bendamustine is not licensed in this indication Note: Can be used in combination with Rituximab, which is commissioned by NHS England for this indication.

[NHS funded]{.badge .rounded-pill .bg-success} From: 08 July 2018

Form version:

CDF Managed Access: NA

NICE Technology Appraisal: - NHS England clinical policy (NA)

Current Form Version

Important

This is an older version of the form. To view the most up to date form follow this link

Older Form Versions

There are previous versions of this form. These may not all be available on this site.